The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1L9AQ6     (2S)-2-amino-3-(3,4- dihydroxyphenyl)propan...

Synonyms: C06870, 57308-51-7, Carbidopa-levodopa
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C06870


Psychiatry related information on C06870


High impact information on C06870


Chemical compound and disease context of C06870


Biological context of C06870


Anatomical context of C06870


Gene context of C06870


Analytical, diagnostic and therapeutic context of C06870


  1. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. Friedman, J.H., Feinberg, S.S., Feldman, R.G. JAMA (1985) [Pubmed]
  2. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma. Pierson, H.F., Meadows, G.G. Cancer Res. (1983) [Pubmed]
  3. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Gwinn-Hardy, K., Chen, J.Y., Liu, H.C., Liu, T.Y., Boss, M., Seltzer, W., Adam, A., Singleton, A., Koroshetz, W., Waters, C., Hardy, J., Farrer, M. Neurology (2000) [Pubmed]
  4. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide). Ahlskog, J.E., Muenter, M.D., Bailey, P.A., Stevens, P.M. Arch. Neurol. (1992) [Pubmed]
  5. Carbidopa-levodopa therapy for movement disorders. Sohn, D.G., Hoerning, E., Kaplan, P.E. Archives of physical medicine and rehabilitation. (1987) [Pubmed]
  6. Entacapone in restless legs syndrome. Sharif, A.A. Mov. Disord. (2002) [Pubmed]
  7. Apraxia of lid opening: dose-dependent response to carbidopa-levodopa. Lee, K.C., Finley, R., Miller, B. Pharmacotherapy (2004) [Pubmed]
  8. Carbidopa-levodopa-induced recrudescence of premorbid tic disorder in remission. Latif, T., Leo, R.J., Bakhai, Y.D. Primary care companion to the Journal of clinical psychiatry. (2005) [Pubmed]
  9. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Garber, C.E., Friedman, J.H. Neurology (2003) [Pubmed]
  10. Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study. Capildeo, R. Neurology (1998) [Pubmed]
  11. Clinical and genetic analysis of progressive dystonia with diurnal variation. Fink, J.K., Ravin, P.D., Filling-Katz, M., Argoff, C.E., Hallett, M. Arch. Neurol. (1991) [Pubmed]
  12. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease. Hutton, J.T., Albrecht, J.W., Román, G.C., Kopetzky, M.T. Arch. Neurol. (1988) [Pubmed]
  13. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. Hoehn, M.M. Arch. Neurol. (1980) [Pubmed]
  14. Rehabilitation of patients with Hallervorden-Spatz syndrome. Seibel, M.O., Date, E.S., Zeiner, H., Schwartz, M. Archives of physical medicine and rehabilitation. (1993) [Pubmed]
  15. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation. Cedarbaum, J.M., Clark, M., Toy, L.H., Green-Parsons, A. Mov. Disord. (1990) [Pubmed]
  16. Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease. Lee, S.T., Lu, C.S. J. Formos. Med. Assoc. (1996) [Pubmed]
  17. Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability. Contin, M., Riva, R., Martinelli, P., Procaccianti, G., Baruzzi, A. Clinical neuropharmacology. (1989) [Pubmed]
  18. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Benetello, P., Furlanut, M., Fortunato, M., Pea, F., Baraldo, M. Pharmacol. Res. (1997) [Pubmed]
  19. Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report. Doe, J. J. Nerv. Ment. Dis. (1987) [Pubmed]
  20. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy. Meadows, G.G., Pierson, H.F., Abdallah, R.M., Desai, P.R. Cancer Res. (1982) [Pubmed]
  21. Treatment of Parkinson's disease with pergolide: a double-blind study. Ahlskog, J.E., Muenter, M.D. Mayo Clin. Proc. (1988) [Pubmed]
  22. Maximizing the benefit of pharmacotherapy in Parkinson's disease. Berchou, R.C. Pharmacotherapy (2000) [Pubmed]
WikiGenes - Universities